Chutes & Ladders—Atai appoints co-CEO and a Fierce goodbye
Chutes & Ladders—Atai appoints co-CEO and a Fierce goodbye gmasson Thu, 05/16/2024 - 15:18
Chutes & Ladders—Atai appoints co-CEO and a Fierce goodbye gmasson Thu, 05/16/2024 - 15:18
J&J hooks Proteologix for $850M cash, reeling in a roster of early bispecifics mbayer Thu, 05/16/2024 - 10:23
Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data jwaldron Thu, 05/16/2024 - 09:29
AstraZeneca prepares fresh COVID push to regulators after antibody's phase 3 success jwaldron Thu, 05/16/2024 - 07:17
Lilly keeps on Novo's tail by reporting weekly insulin hits primary endpoint in 2 pivotal trials ntaylor Thu, 05/16/2024 - 05:49
Roche's $2.7B Carmot bet pays off with phase 1 weight loss success for GLP-1/GIP agonist jwaldron Thu, 05/16/2024 - 05:30